Avalo Therapeutics, Inc. (NASDAQ:AVTX) Receives $32.71 Consensus Price Target from Analysts

Avalo Therapeutics, Inc. (NASDAQ:AVTX) has been given a consensus rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $32.7143.

AVTX has been the subject of several recent research reports. HC Wainwright reaffirmed a “buy” rating and issued a $25.00 price target on shares of Avalo Therapeutics in a report on Thursday, January 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Avalo Therapeutics in a report on Friday, January 9th. Mizuho raised shares of Avalo Therapeutics to a “strong-buy” rating in a research report on Thursday, December 18th. Finally, BTIG Research reissued a “buy” rating and issued a $40.00 price objective on shares of Avalo Therapeutics in a report on Monday, September 29th.

Avalo Therapeutics Trading Up 6.5%

AVTX opened at $15.76 on Monday. Avalo Therapeutics has a twelve month low of $3.39 and a twelve month high of $20.72. The firm has a market capitalization of $291.72 million, a PE ratio of -2.94 and a beta of 0.84. The firm’s 50-day moving average price is $17.58 and its 200 day moving average price is $13.34.

Avalo Therapeutics (NASDAQ:AVTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($2.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.67) by ($0.52). As a group, analysts predict that Avalo Therapeutics will post -19.07 earnings per share for the current fiscal year.

Institutional Trading of Avalo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Orbimed Advisors LLC lifted its holdings in Avalo Therapeutics by 39.5% in the third quarter. Orbimed Advisors LLC now owns 1,349,300 shares of the company’s stock valued at $17,150,000 after acquiring an additional 382,300 shares during the last quarter. Nantahala Capital Management LLC raised its position in Avalo Therapeutics by 24.1% in the third quarter. Nantahala Capital Management LLC now owns 1,235,000 shares of the company’s stock valued at $15,697,000 after purchasing an additional 240,000 shares during the period. Caligan Partners LP acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at $10,592,000. Balyasny Asset Management L.P. acquired a new position in shares of Avalo Therapeutics in the 3rd quarter valued at $10,390,000. Finally, Vanguard Group Inc. grew its holdings in shares of Avalo Therapeutics by 314.9% during the 3rd quarter. Vanguard Group Inc. now owns 692,637 shares of the company’s stock worth $8,803,000 after purchasing an additional 525,696 shares during the period. Institutional investors and hedge funds own 87.06% of the company’s stock.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company’s proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.